CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more
CMG Pharmaceutical Co. Ltd (058820) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.020x
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) has a cash flow conversion efficiency ratio of -0.020x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.04 Billion) by net assets (₩204.41 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CMG Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how CMG Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CMG Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CMG Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tethys Oil AB
ST:TETY
|
0.057x |
|
SIERRA MADRE GOLD AND SIL
F:409
|
N/A |
|
Caswell Inc
TW:6416
|
-0.038x |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
-0.016x |
|
Audix Corp
TW:2459
|
-0.006x |
|
Guan Chong Bhd
KLSE:5102
|
0.169x |
|
Frontera Energy Corp
PINK:FECCF
|
0.093x |
|
i-SENS Inc
KQ:099190
|
0.018x |
Annual Cash Flow Conversion Efficiency for CMG Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of CMG Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩189.54 Billion | ₩290.09 Million | 0.002x | -92.55% |
| 2023-12-31 | ₩190.23 Billion | ₩3.91 Billion | 0.021x | -23.03% |
| 2022-12-31 | ₩184.95 Billion | ₩4.94 Billion | 0.027x | -12.40% |
| 2021-12-31 | ₩184.70 Billion | ₩5.63 Billion | 0.030x | +87.47% |
| 2020-12-31 | ₩181.13 Billion | ₩2.94 Billion | 0.016x | +3.72% |
| 2019-12-31 | ₩180.16 Billion | ₩2.82 Billion | 0.016x | +83.76% |
| 2018-12-31 | ₩103.98 Billion | ₩886.78 Million | 0.009x | -57.12% |
| 2017-12-31 | ₩97.94 Billion | ₩1.95 Billion | 0.020x | -12.90% |
| 2016-12-31 | ₩101.11 Billion | ₩2.31 Billion | 0.023x | -55.67% |
| 2015-12-31 | ₩46.81 Billion | ₩2.41 Billion | 0.052x | +248.22% |
| 2014-12-31 | ₩49.00 Billion | ₩724.89 Million | 0.015x | -- |